Condition: Coronary Catheterization · Sponsor: Associazione per lo Studio delle Malattie Cardiovascolari Cardiva ONLUS
Meta-analysis results show that distal radial access (DRA) is associated with a significant reduction in the risk of radial artery occlusion compared to conventional transradial access (TRA). This is of paramount importance in an evolving interventional context where an increasing number of radial access procedures are being performed to address a growing number of independent health conditions. DRA is also associated with a lower rate of vascular access-related adverse events, establishing it as the safest vascular access ever. However, available data show that the success rate of DRA is lower than that of conventional TRA. Also, while the duration of hemostasis has been shown to be shorter, it has most likely not yet reached its full potential for shortening. Thus, the two extreme phases of DRA require important further evaluation. The CompAring uLtrasound-guided Puncture and advanced HemostAsis to cOnventional approaches in distal radial access: a dual randoMizEd praGmatic triAl (ALPHA\&OMEGA) trial will address this lack of knowledge by exploring whether a significantly shorter hemostasis duration can be achieved with DRA when using hemostasis enhancement and exploring whether ultrasound-guided puncture can increase the success rate of DRA.
This description comes directly from the study's public registry record.
Gregory A Sgueglia, MD, PhD · +390651002864 · g.a.sgueglia@gmail.com
Always discuss trial participation with your own doctor first.
| Groupe Vivalia, Clinique Saint-Joseph | Arlon, Belgium | Recruiting |
| CHU Charleroi-Chimay, Marie Curie Hospital | Charleroi, Belgium | Recruiting |
| CHU Helora, Jolimont Hospital | La Louvière, Belgium | Recruiting |
| Sant'Eugenio Hospital | Roma, RM, Italy | Recruiting |
| Sandro Pertini Hospital | Roma, RM, Italy | Recruiting |
| Mater Salutis Hospital | Legnago, VR, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06835829